Distressed Software Firm Symplr to Get Injection From Private Equity Backers
Clearlake CapitalCompany
Ares CapitalInvestor
Symplr Software secured a $175 million preferred equity injection from its private‑equity owners Clearlake Capital Group and Charlesbank Capital Partners on Sept. 21, 2026, alongside a $103.5 million first‑out second‑lien loan from Ares Capital Corp. The financing is part of a restructuring that reshapes the company’s capital stack and extends debt maturities.
Symplr Software secured a $175 million preferred equity injection from its private‑equity backers Clearlake Capital Group and Charlesbank Capital Partners on Sept. 21, 2026, as part of a broader restructuring aimed at stabilizing the distressed health‑tech SaaS provider.
Deal Terms
The equity infusion is paired with a $103.5 million first‑out second‑lien loan led by Ares Capital Corp. Under the agreement, Clearlake and Charlesbank will defer interest on the new junior‑ranking paper, while existing second‑lien lenders receive a 100‑basis‑point coupon bump. First‑lien lenders to the $1.2 billion term loan due 2027 also get a 100‑bp bump in exchange for extending the maturity by three years, and tighter covenant protections are being added. The restructuring creates multiple debt securities and pushes repayment timelines further into the future.
Background
Symplr’s credit profile has deteriorated sharply since early 2026, when AI‑related market turbulence triggered markdowns across software‑company loan values. Its first‑lien term loan fell to 71.4 cents on the dollar, down from 78 cents in March, while the $290 million second‑lien loan traded at 70 cents. Moody’s downgraded the company into deeper junk in July, reflecting heightened restructuring risk. The new financing is designed to conserve cash, improve covenant coverage, and give the company breathing room to refocus on its core credential‑management and compliance SaaS suite.
The capital raise also signals that private‑equity owners remain committed to a turnaround rather than an outright sale. By converting a portion of the capital structure to preferred equity, Clearlake and Charlesbank gain upside participation while shielding existing debt holders from further dilution. For Ares Capital Corp, the first‑out second‑lien position offers a senior claim on cash flows, aligning with its strategy of backing distressed SaaS assets that retain recurring revenue streams.
Industry observers note that health‑tech SaaS firms are feeling the aftershocks of the AI hype correction, with many seeing tighter credit conditions and heightened scrutiny on cash burn. Symplr’s restructuring mirrors a broader trend where private‑equity sponsors inject equity to preserve strategic platforms rather than exit at distressed valuations.
Why It Matters
For Symplr, the infusion of preferred equity and the new second‑lien facility create a clearer hierarchy of claims, allowing the company to preserve cash for product development and customer retention at a time when health‑tech buyers are tightening spend. The extended maturities and coupon bumps reduce immediate cash‑flow pressure, giving the management team a runway to stabilize ARR and improve net revenue retention without resorting to a fire‑sale.
Competitors such as Veeva Systems and Athenahealth, which operate in adjacent credential‑management and compliance niches, now face a Symplr that can potentially re‑invest in AI‑enabled automation and integration features that were previously deferred. Meanwhile, Clearlake, Charlesbank, and Ares demonstrate a willingness to double‑down on distressed SaaS assets, suggesting that private‑equity capital will continue to flow into turnaround opportunities rather than exiting the sector entirely.
Key Points
- Symplr received a $175 million preferred equity injection from Clearlake Capital Group and Charlesbank Capital Partners.
- Ares Capital Corp is providing a $103.5 million first‑out second‑lien loan as part of the restructuring.
- Existing lenders receive a 100‑basis‑point coupon bump and first‑lien maturities are extended by three years.
- Symplr’s first‑lien term loan traded at 71.4 cents on the dollar, down from 78 cents in March 2026.
- Moody’s downgraded Symplr into deeper junk in July 2026, prompting the capital‑structure overhaul.
Analysis
The $175 million equity injection values Symplr at a multiple that is likely below the 8‑10x ARR range typical for high‑growth health‑tech SaaS firms, reflecting the company’s distressed credit profile and recent AI‑related market headwinds. By converting part of the capital structure to preferred equity, the backers secure upside participation while preserving the company’s recurring revenue base, which remains attractive to credit investors seeking stable cash flows. The broader trend of private‑equity sponsors stepping in with equity rather than exiting underscores a market where growth rates have stalled but subscription revenues remain resilient. Operators should note that extending debt maturities and adding coupon bumps can improve covenant coverage, but they also increase the cost of capital, pressuring gross margins. For investors, the deal highlights a pricing discount on distressed SaaS assets, offering potential upside if the company can rebound its ARR growth and net revenue retention. The financing also signals that credit markets are still willing to fund senior‑secured debt for health‑tech platforms that can demonstrate predictable cash‑flow streams, even as overall private‑credit conditions tighten.